Matisyahu Shulman
Overview
Explore the profile of Matisyahu Shulman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shulman M, Choo T, Ohrtman K, Pavlicova M, Rotrosen J, Nunes E
Drug Alcohol Depend
. 2025 Feb;
268:112550.
PMID: 39892089
Aims: Cannabis use is highly prevalent in patients seeking treatment for opioid use disorder. Studies have shown mixed results on the association between cannabis use and opioid use as well...
2.
Shulman M, Meyers-Ohki S, Novo P, Provost S, Ohrtman K, Van Veldhuisen P, et al.
Contemp Clin Trials
. 2025 Jan;
150:107816.
PMID: 39842691
Introduction And Background: The three medications approved to address OUD are effective in decreasing opioid use and morbidity and mortality; however, their utility is limited by high rates of dropout...
3.
Ross R, Inose S, Shulman M, Nunes E, Zalla L, Burlew A, et al.
JAMA Netw Open
. 2024 Oct;
7(10):e2436612.
PMID: 39365581
Importance: Racial and ethnic disparities in access to treatment and quality of treatment for opioid use disorder (OUD) have been identified in usual care settings. In contrast, disparities in treatment...
4.
Ross R, Nunes E, Olfson M, Shulman M, Krawczyk N, Stuart E, et al.
Addiction
. 2024 Aug;
119(11):1975-1986.
PMID: 39099417
Background And Aims: Extended-release naltrexone (XR-NTX) and sublingual buprenorphine (SL-BUP) are both approved for opioid use disorder (OUD) treatment in any medical setting. We aimed to compare the real-world effectiveness...
5.
Shulman M, Greiner M, Tafessu H, Opara O, Ohrtman K, Potter K, et al.
JAMA Netw Open
. 2024 May;
7(5):e249744.
PMID: 38717773
Importance: Injectable extended-release (XR)-naltrexone is an effective treatment option for opioid use disorder (OUD), but the need to withdraw patients from opioid treatment prior to initiation is a barrier to...
6.
Shulman M, Provost S, Ohrtman K, Novo P, Meyers-Ohki S, Van Veldhuisen P, et al.
Contemp Clin Trials
. 2024 Apr;
142:107543.
PMID: 38657730
Introduction And Background: Buprenorphine, and extended-release naltrexone, are effective in decreasing opioid use, morbidity and mortality. The available evidence suggests that these medications should be used for long term treatment;...
7.
Ross R, Nunes E, Olfson M, Shulman M, Krawczyk N, Stuart E, et al.
medRxiv
. 2024 Feb;
PMID: 38343815
Aims: To compare the real-world effectiveness of extended release naltrexone (XR-NTX) and sublingual buprenorphine (SL-BUP) for the treatment of opioid use disorder (OUD). Design: An observational active comparator, new user...
8.
Shulman M, Greiner M, Bisaga A
Addiction
. 2023 Oct;
119(1):158-159.
PMID: 37853655
No abstract available.
9.
Shulman M, Choo T, Scodes J, Pavlicova M, Novo P, Campbell A, et al.
J Addict Med
. 2023 Oct;
17(5):618-620.
PMID: 37788622
Objectives: Timeline follow-back (TLFB) is a self-report measure commonly used as a method of assessing historical drug use in both clinical and research settings. Our study considered rates of agreement...
10.
Greiner M, Shulman M, Opara O, Potter K, Voronca D, Tafessu H, et al.
Contemp Clin Trials
. 2023 Mar;
128:107148.
PMID: 36931426
Background: Extended-release injectable naltrexone (XR-NTX) is an effective treatment for opioid use disorder (OUD), but initiation remains a barrier to implementation. Standard practice requires a 10- to 15-day inpatient admission...